- Betamethasone lotion price philippines
Looking for:
- Betnovate Full Prescribing Information, Dosage & Side Effects | MIMS Philippines |
localhost : Philippine Online Drugstore forBranded, Generics and more…
Udcacid is taken from the digestive system and passes via enterohepatic recirculation. There is mg of ursodeoxycholic acid [ Tacrotec is an immunosuppressive drug. After a kidney, liver, or cardiac surgery, it is used to avoid organ rejection if [ Tacromax comes in the form of gelatin capsules with a firm shell and 1 mg of anhydrous tacrolimus powder that [ Indications This medication is used to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Contraindications Should not be given to patients with hypersensitivity reactions from this drug. How to use betamethasone This medicine is usually applied 1 to 3 times daily. Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended. Do not take by mouth. Betamethasone topical is for use only on the skin.
Wash your hands before and after using betamethasone topical, unless you are using the medicine to treat the skin on your hands. Apply a small amount to the affected area and rub it gently into the skin. Do not apply betamethasone topical over a large area of skin. Do not cover the treated skin area unless your doctor tells you to. Covering the skin that is treated with betamethasone topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects.
When treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Use betamethasone topical regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely. Call your doctor if your skin condition does not improve after several days of treatment, or if it gets worse while using betamethasone topical. Side Effects. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.
Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary-free cortisol and ACTH stimulation tests.
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity.
Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage or misuse the features of hypercortisolism may occur see Adverse Effects. Treatment: In the event of overdose, Betnovate should be withdrawn gradually by reducing the frequency of application, or by substituting a less potent corticosteroid because of the risk of glucocorticosteroid insufficiency.
Further management should be as clinically indicated or as recommended by the National Poisons Center, where available. The following conditions should not be treated with Betnovate: Untreated cutaneous infection, rosacea, acne vulgaris, pruritus without inflammation, perianal and genital pruritus and perioral dermatitis.
Special Precautions. Hypersensitivity to corticosteroids or to any of the excipients in the preparation. Local hypersensitivity reactions may resemble symptoms of the condition under treatment see Adverse Reactions. Manifestations of hypercortisolism Cushing's syndrome and reversible hypothalamic-pituitary-adrenal HPA axis suppression, leading to glucocorticosteroid insufficiency, can occur in some individuals as a result of increased systemic absorption of topical steroids.
If either of the previously mentioned are observed, withdraw the drug gradually by reducing the frequency of application, or by substituting a less potent corticosteroid. Abrupt withdrawal of treatment may result in glucocorticosteroid insufficiency see Adverse Reactions. Risk factors for increased systemic effects are: Potency and formulation of topical steroid, duration of exposure, application to a large surface area, use on occluded areas of skin eg, on intertriginous areas or under occlusive dressings in infants the nappy may act as an occlusive dressing , increased hydration of the stratum corneum, use on thin skin areas eg, the face, use on broken skin or other conditions where the skin barrier may be impaired and in comparison with adults, children may absorb proportionally larger amounts of topical corticosteroids and thus, be more susceptible to systemic adverse effects.
This is because children have an immature skin barrier and a greater surface area to body weight ratio compared with adults. Infection Risk with Occlusion: Bacterial infection is encouraged by the warm, moist conditions induced by occlusive dressings and so the skin should be cleansed before a fresh dressing is applied.
Use in Psoriasis: Topical corticosteroids may be hazardous in psoriasis for a number of reasons including rebound relapses, development of tolerances, risk of generalized pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin have been reported in some cases.
If used in psoriasis, careful patient supervision is important. Application to the Face: Prolonged application to the face is undesirable as this area is more susceptible to atrophic changes. Application to the Eyelids: If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as cataract and glaucoma might result from repeated exposure.
Concomitant Infection: Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected. Any spread of infection requires withdrawal of topical corticosteroid therapy and administration of antimicrobial agents.
Chronic Leg Ulcers: Topical corticosteroids are sometimes used to treat the dermatitis around chronic leg ulcers. However, this use may be associated with a higher occurrence of local hypersensitivity reactions and an increased risk of local infection. Effects on Ability to Drive or Operate Machinery: There have been no studies to investigate the effect of Betnovate on driving performance or the ability to operate machinery.
A detrimental effect on such activities would not be anticipated from the adverse reaction profile of topical Betnovate. Impairment of Fertility: There are no data in humans to evaluate the effect of topical corticosteroids on fertility.
Use in pregnancy: There are limited data from the use of Betnovate in pregnant women. Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development see Pharmacology: Toxicology under Actions. The relevance of this finding to human beings has not been established; however, administration of Betnovate during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the fetus.
The minimum quantity should be used for the minimum duration. Use in lactation: The safe use of topical corticosteroids during lactation has not been established.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of Betnovate during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant.
If used during lactation, Betnovate should not be applied to the breasts to avoid accidental ingestion by the infant. Adverse Reactions. Drug Interactions. Co-administered drugs that can inhibit CYP3A4 eg, ritonavir, itraconazole have been shown to inhibit the metabolism of corticosteroids leading to increased systemic exposure. The extent to which this interaction is clinically relevant depends on the dose and route of administration of the corticosteroids and the potency of the CYP3A4 inhibitor.
Incompatibilities: No incompatibilities have been identified. Contents are flammable. Keep away from fine, flame or heat. Protect from light or direct sunlight. MIMS Class.
Topical Corticosteroids. ATC Classification. Used in the treatment of dermatological diseases.
❾-50%}Keep all medicines away from children and pets. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product. Udcacid is taken from the digestive system and passes via enterohepatic recirculation. There is mg of ursodeoxycholic acid [ Tacrotec is an immunosuppressive drug.
After a kidney, liver, or cardiac surgery, it is used to avoid organ rejection if [ Tacromax comes in the form of gelatin capsules with a firm shell and 1 mg of anhydrous tacrolimus powder that [ Indications This medication is used to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Contraindications Should not be given to patients with hypersensitivity reactions from this drug. How to use betamethasone This medicine is usually applied 1 to 3 times daily.
Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended. Do not take by mouth. Betamethasone topical is for use only on the skin. Wash your hands before and after using betamethasone topical, unless you are using the medicine to treat the skin on your hands.
Apply a small amount to the affected area and rub it gently into the skin. Do not apply betamethasone topical over a large area of skin. Do not cover the treated skin area unless your doctor tells you to. Covering the skin that is treated with betamethasone topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. When treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers.
Use betamethasone topical regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely. Call your doctor if your skin condition does not improve after several days of treatment, or if it gets worse while using betamethasone topical. Side Effects. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.
Impairment of Fertility: The effect on fertility of betamethasone valerate has not been evaluated in animals. These include atopic dermatitis including infantile atopic dermatitis , nummular dermatitis discoid eczema , prurigo nodularis, psoriasis excluding widespread plague psoriasis , lichen simplex chronicus neurodermatitis and lichen planus, seborrhoeic dermatitis, irritant or allergic contact dermatitis, discoid lupus erythomatosus, adjunct to systemic steroid therapy in generalized erythroderma, insect bite reactions and miliaria prickly heat.
Creams: For moist or weeping surfaces. Ointments: For dry, lichenified or scaly lesions. Apply thinly and gently rub in using only enough to cover the entire affected area once or twice daily for up to 4 weeks until improvement occurs, then reduce the frequency of application or change the treatment to a less potent preparation.
Allow adequate time for absorption after each application before applying an emollient. In the more resistant lesions eg, the thickened plaques of psoriasis on elbows and knees, the effect of Betnovate can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response in such lesions; thereafter, improvement can usually be maintained by regular application without occlusion.
If the condition worsens or does not improve within weeks, treatment and diagnosis should be re-evaluated. Atopic Dermatitis Eczema : Therapy with Betnovate should be gradually discontinued once control is achieved and an emollient continued as maintenance therapy.
Rebound of preexisting dermatoses can occur with abrupt discontinuation of Betnovate. Recalcitrant Dermatoses: Patients Who Frequently Relapse: Once an acute episode has been treated effectively with a continuous course of topical corticosteroid, intermittent dosing once daily, twice weekly, without occlusion may be considered. This has been shown to be helpful in reducing the frequency of relapse. Application should be continued to all previously affected sites or to known sites of potential relapse.
This regimen should be combined with routine daily use of emollients. The condition and the benefits and risks of continued treatment must be re-evaluated on a regular basis. They are more likely to develop local and systemic side effects of topical corticosteroids and in general, require shorter courses and less potent agents than adults.
Care should be taken when using Betnovate to ensure the amount applied is the minimum that provides therapeutic benefit. Elderly: Clinical studies have not identified differences in responses between the elderly and younger patients. The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs.
Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit. Renal and Hepatic Impairment: In case of systemic absorption when application is over a large surface area for a prolonged period metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity.
Administration: Due to inflammable nature of Betnovate lotion, patients should avoid smoking or being near an open flame during application and immediately after use. Symptoms: Topically applied betamethasone valerate may be absorbed in sufficient amounts to produce systemic effects. Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage or misuse the features of hypercortisolism may occur see Adverse Effects. Treatment: In the event of overdose, Betnovate should be withdrawn gradually by reducing the frequency of application, or by substituting a less potent corticosteroid because of the risk of glucocorticosteroid insufficiency.
Further management should be as clinically indicated or as recommended by the National Poisons Center, where available. The following conditions should not be treated with Betnovate: Untreated cutaneous infection, rosacea, acne vulgaris, pruritus without inflammation, perianal and genital pruritus and perioral dermatitis. Special Precautions. Hypersensitivity to corticosteroids or to any of the excipients in the preparation. Local hypersensitivity reactions may resemble symptoms of the condition under treatment see Adverse Reactions.
Manifestations of hypercortisolism Cushing's syndrome and reversible hypothalamic-pituitary-adrenal HPA axis suppression, leading to glucocorticosteroid insufficiency, can occur in some individuals as a result of increased systemic absorption of topical steroids. If either of the previously mentioned are observed, withdraw the drug gradually by reducing the frequency of application, or by substituting a less potent corticosteroid.
Abrupt withdrawal of treatment may result in glucocorticosteroid insufficiency see Adverse Reactions. Risk factors for increased systemic effects are: Potency and formulation of topical steroid, duration of exposure, application to a large surface area, use on occluded areas of skin eg, on intertriginous areas or under occlusive dressings in infants the nappy may act as an occlusive dressing , increased hydration of the stratum corneum, use on thin skin areas eg, the face, use on broken skin or other conditions where the skin barrier may be impaired and in comparison with adults, children may absorb proportionally larger amounts of topical corticosteroids and thus, be more susceptible to systemic adverse effects.
This is because children have an immature skin barrier and a greater surface area to body weight ratio compared with adults. Infection Risk with Occlusion: Bacterial infection is encouraged by the warm, moist conditions induced by occlusive dressings and so the skin should be cleansed before a fresh dressing is applied. Use in Psoriasis: Topical corticosteroids may be hazardous in psoriasis for a number of reasons including rebound relapses, development of tolerances, risk of generalized pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin have been reported in some cases.
If used in psoriasis, careful patient supervision is important. Application to the Face: Prolonged application to the face is undesirable as this area is more susceptible to atrophic changes. Application to the Eyelids: If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as cataract and glaucoma might result from repeated exposure. Concomitant Infection: Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected.
Any spread of infection requires withdrawal of topical corticosteroid therapy and administration of antimicrobial agents. Chronic Leg Ulcers: Topical corticosteroids are sometimes used to treat the dermatitis around chronic leg ulcers.
Description: Betamethasone is a corticosteroid that prevents and controls inflammation by playing a role in cellular signaling, immune function, inflammation, and protein regulation. This medication is used to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.
Consult your doctor for more details. Lifestyle changes that may help reduce the risk of brittle bones osteoporosis while taking this drug for an extended time include doing weight-bearing exercise, stopping smoking, getting enough calcium and vitamin D, and limiting alcohol.
Discuss with your doctor lifestyle changes that might benefit you. If you take this medication for long-term treatment, wear or carry identification stating that you are using it. See also Medical Alert section. Missed Dose: If you are taking this medication once daily and miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up. Ask your doctor ahead of time what you should do if you miss a dose while taking this medication every other day or on another schedule besides a daily one.
Storage: Store at room temperature between degrees F degrees C away from light and moisture. Do not store in the bathroom. Do not freeze. Discard medication that has been frozen. Keep all medicines away from children and pets. Do not flush medications down the toilet or pour them into a drain unless instructed to do so.
Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Udcacid is taken from the digestive system and passes via enterohepatic recirculation. There is mg of ursodeoxycholic acid [ Tacrotec is an immunosuppressive drug. After a kidney, liver, or cardiac surgery, it is used to avoid organ rejection if [ Tacromax comes in the form of gelatin capsules with a firm shell and 1 mg of anhydrous tacrolimus powder that [ Indications This medication is used to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Contraindications Should not be given to patients with hypersensitivity reactions from this drug. How to use betamethasone This medicine is usually applied 1 to 3 times daily. Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended.
Do not take by mouth. Betamethasone topical is for use only on the skin. Wash your hands before and after using betamethasone topical, unless you are using the medicine to treat the skin on your hands. Apply a small amount to the affected area and rub it gently into the skin. Do not apply betamethasone topical over a large area of skin. Do not cover the treated skin area unless your doctor tells you to. Covering the skin that is treated with betamethasone topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects.
When treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Use betamethasone topical regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely. Call your doctor if your skin condition does not improve after several days of treatment, or if it gets worse while using betamethasone topical. Side Effects. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.
Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary-free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity.
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
If your doctor has directed you to take low-dose aspirin for heart attack or stroke prevention usually at dosages of milligrams a dayyou should continue taking it unless your doctor instructs you otherwise. Ask your doctor or pharmacist for more details. Overdose If overdose is suspected, contact a poison control center or emergency room immediately.
Notes: Do not share this medication with others.
Betamethasone valerate % Topical Ointment 5g. Betamethasone Lotion ; Betamethasone Lotion (ml). ₱ ; CLOBETASOL% LOTION (ml). ₱ ; g Betamethasone Cream.1%. ₱1, ; Clobetasol. CONNECT WITH US. View as. Sorting. Best selling; Title descending; Title ascending; Price ascending; Price descending. Rx: Betnovate Plain % 20 ml Lotion. Add To Cart. Betamethasone valerate % Topical Ointment 5g. Rebound of preexisting dermatoses can occur with abrupt discontinuation of Betnovate. Do not take by mouth. In addition, some corticosteroids and their metabolites are also excreted in the bile.Manufacturer: GlaxoSmithKline. Distributor: Zuellig. Full Prescribing Info. Pharmacology: Mechanism of Action: Topical corticosteroids act as anti-inflammatory agents via multiple mechanisms to inhibit late phase allergic reactions including decreasing the density of mast cells, decreasing chemotaxis and activation of eosinophils, decreasing cytokine production by lymphocytes, monocytes, mast cells and eosinophils, and inhibiting the metabolism of arachidonic acid.
Pharmacodynamic Effect: Topical corticosteroids have anti-inflammatory, antipruritic and vasoconstrictive properties. Pharmacokinetics: Absorption: Topical corticosteroids can be systemically absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Distribution: The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids is necessary because circulating levels are well below the level of detection.
Metabolism: Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. They are metabolised, primarily in the liver.
Elimination: Topical corticosteroids are excreted by the kidneys. In addition, some corticosteroids and their metabolites are also excreted in the bile. Toxicology: Preclinical Safety Data: Carcinogenicity: Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone valerate. Genotoxicity: No specific studies have been conducted to investigate the genotoxic potential of betamethasone valerate.
Impairment of Fertility: The effect on fertility of betamethasone valerate has not been evaluated in animals. These include atopic dermatitis including infantile atopic dermatitis , nummular dermatitis discoid eczema , prurigo nodularis, psoriasis excluding widespread plague psoriasis , lichen simplex chronicus neurodermatitis and lichen planus, seborrhoeic dermatitis, irritant or allergic contact dermatitis, discoid lupus erythomatosus, adjunct to systemic steroid therapy in generalized erythroderma, insect bite reactions and miliaria prickly heat.
Creams: For moist or weeping surfaces. Ointments: For dry, lichenified or scaly lesions. Apply thinly and gently rub in using only enough to cover the entire affected area once or twice daily for up to 4 weeks until improvement occurs, then reduce the frequency of application or change the treatment to a less potent preparation.
Allow adequate time for absorption after each application before applying an emollient. In the more resistant lesions eg, the thickened plaques of psoriasis on elbows and knees, the effect of Betnovate can be enhanced, if necessary, by occluding the treatment area with polythene film.
Overnight occlusion only is usually adequate to bring about a satisfactory response in such lesions; thereafter, improvement can usually be maintained by regular application without occlusion. If the condition worsens or does not improve within weeks, treatment and diagnosis should be re-evaluated. Atopic Dermatitis Eczema : Therapy with Betnovate should be gradually discontinued once control is achieved and an emollient continued as maintenance therapy.
Rebound of preexisting dermatoses can occur with abrupt discontinuation of Betnovate. Recalcitrant Dermatoses: Patients Who Frequently Relapse: Once an acute episode has been treated effectively with a continuous course of topical corticosteroid, intermittent dosing once daily, twice weekly, without occlusion may be considered.
This has been shown to be helpful in reducing the frequency of relapse. Application should be continued to all previously affected sites or to known sites of potential relapse. This regimen should be combined with routine daily use of emollients. The condition and the benefits and risks of continued treatment must be re-evaluated on a regular basis.
They are more likely to develop local and systemic side effects of topical corticosteroids and in general, require shorter courses and less potent agents than adults. Care should be taken when using Betnovate to ensure the amount applied is the minimum that provides therapeutic benefit. Elderly: Clinical studies have not identified differences in responses between the elderly and younger patients. The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs.
Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit. Renal and Hepatic Impairment: In case of systemic absorption when application is over a large surface area for a prolonged period metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity. Administration: Due to inflammable nature of Betnovate lotion, patients should avoid smoking or being near an open flame during application and immediately after use.
Symptoms: Topically applied betamethasone valerate may be absorbed in sufficient amounts to produce systemic effects. Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage or misuse the features of hypercortisolism may occur see Adverse Effects.
Treatment: In the event of overdose, Betnovate should be withdrawn gradually by reducing the frequency of application, or by substituting a less potent corticosteroid because of the risk of glucocorticosteroid insufficiency. Further management should be as clinically indicated or as recommended by the National Poisons Center, where available. The following conditions should not be treated with Betnovate: Untreated cutaneous infection, rosacea, acne vulgaris, pruritus without inflammation, perianal and genital pruritus and perioral dermatitis.
Special Precautions. Hypersensitivity to corticosteroids or to any of the excipients in the preparation. Local hypersensitivity reactions may resemble symptoms of the condition under treatment see Adverse Reactions.
Manifestations of hypercortisolism Cushing's syndrome and reversible hypothalamic-pituitary-adrenal HPA axis suppression, leading to glucocorticosteroid insufficiency, can occur in some individuals as a result of increased systemic absorption of topical steroids.
If either of the previously mentioned are observed, withdraw the drug gradually by reducing the frequency of application, or by substituting a less potent corticosteroid. Abrupt withdrawal of treatment may result in glucocorticosteroid insufficiency see Adverse Reactions. Risk factors for increased systemic effects are: Potency and formulation of topical steroid, duration of exposure, application to a large surface area, use on occluded areas of skin eg, on intertriginous areas or under occlusive dressings in infants the nappy may act as an occlusive dressing , increased hydration of the stratum corneum, use on thin skin areas eg, the face, use on broken skin or other conditions where the skin barrier may be impaired and in comparison with adults, children may absorb proportionally larger amounts of topical corticosteroids and thus, be more susceptible to systemic adverse effects.
This is because children have an immature skin barrier and a greater surface area to body weight ratio compared with adults. Infection Risk with Occlusion: Bacterial infection is encouraged by the warm, moist conditions induced by occlusive dressings and so the skin should be cleansed before a fresh dressing is applied. Use in Psoriasis: Topical corticosteroids may be hazardous in psoriasis for a number of reasons including rebound relapses, development of tolerances, risk of generalized pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin have been reported in some cases.
If used in psoriasis, careful patient supervision is important. Application to the Face: Prolonged application to the face is undesirable as this area is more susceptible to atrophic changes. Application to the Eyelids: If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as cataract and glaucoma might result from repeated exposure. Concomitant Infection: Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected.
Any spread of infection requires withdrawal of topical corticosteroid therapy and administration of antimicrobial agents. Chronic Leg Ulcers: Topical corticosteroids are sometimes used to treat the dermatitis around chronic leg ulcers. However, this use may be associated with a higher occurrence of local hypersensitivity reactions and an increased risk of local infection. Effects on Ability to Drive or Operate Machinery: There have been no studies to investigate the effect of Betnovate on driving performance or the ability to operate machinery.
A detrimental effect on such activities would not be anticipated from the adverse reaction profile of topical Betnovate. Impairment of Fertility: There are no data in humans to evaluate the effect of topical corticosteroids on fertility.
Use in pregnancy: There are limited data from the use of Betnovate in pregnant women. Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development see Pharmacology: Toxicology under Actions. The relevance of this finding to human beings has not been established; however, administration of Betnovate during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the fetus.
The minimum quantity should be used for the minimum duration. Use in lactation: The safe use of topical corticosteroids during lactation has not been established. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of Betnovate during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant.
If used during lactation, Betnovate should not be applied to the breasts to avoid accidental ingestion by the infant. Adverse Reactions. Drug Interactions.
Co-administered drugs that can inhibit CYP3A4 eg, ritonavir, itraconazole have been shown to inhibit the metabolism of corticosteroids leading to increased systemic exposure. The extent to which this interaction is clinically relevant depends on the dose and route of administration of the corticosteroids and the potency of the CYP3A4 inhibitor. Incompatibilities: No incompatibilities have been identified.
Contents are flammable. Keep away from fine, flame or heat. Protect from light or direct sunlight. MIMS Class. Topical Corticosteroids. ATC Classification. Used in the treatment of dermatological diseases. Regulatory Classification. Register or sign in to continue. Continue with Google.
Sign Up. Already a member? Sign in.
Comments
Post a Comment